Morgan Keegan Maintains Market Perform Rating and $32 PT on Thoratec
A report from Morgan Keegan reiterates its Market Perform rating and $32 price target on Thoratec (NASDAQ: THOR).
The report states, “Even so, with competition in Europe heating up and sales beginning in earnest in the U.S., there will be some lumpiness. We also know that revenue and earnings estimates may vary greatly and some may get well ahead of what the company guidance. These factors seemed to conspire against Thoratec this quarter. Bottom line: even though the numbers were not that great, they were not that bad either."
THOR closed yesterday at $34.89.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.